Towards progress on DNA vaccines for cancer |
| |
Authors: | D B Lowe M H Shearer C A Jumper R C Kennedy |
| |
Institution: | (1) Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, 3601 4th Street STOP 6591, Lubbock, TX 79430-6591, USA;(2) Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA;(3) Southwest Cancer Treatment and Research Center, Lubbock, TX, USA |
| |
Abstract: | Cancer immunotherapy faces many obstacles that include eliciting immune reactions to self antigens as well as overcoming tumor-derived
immunosuppressive networks and evasion tactics. Within the vaccine arsenal for inhibiting cancer proliferation, plasmid DNA
represents a novel immunization strategy that is capable of eliciting both humoral and cellular arms of the immune response
in addition to being safely administered and easily engineered and manufactured. Unfortunately, while DNA vaccines have performed
well in preventing and treating malignancies in animal models, their overall application in human clinical trials has not
impacted cancer regression to date. Since the establishment of these early trials, progress has been made in terms of increasing
DNA vaccine immunogenicity and subverting the suppressive properties of tumor cells. Therefore, the success of future plasmid
DNA use in cancer patients will depend on combinatorial strategies that enhance and direct the DNA vaccine immune response
while also targeting tumor evasion mechanisms.
Received 2 April 2007; received after revision 14 May 2007; accepted 21 May 2007 |
| |
Keywords: | DNA vaccines cancer immunotherapy non-human primates animal models |
本文献已被 PubMed SpringerLink 等数据库收录! |
|